ArticleJournal of periodontal research2026
Anti-Proliferative Effects of Resveratrol on Gingival Fibroblasts Derived From Amlodipine-Induced Gingival Overgrowth.
Article in Journal of periodontal research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to investigate the anti-proliferative effects of resveratrol on gingival fibroblasts derived from amlodipine-induced gingival overgrowths and its impact on the levels of transforming growth factor-β1 (TGF-β1), connective tissue growth factor (CTGF), collagen type I (COL-1), interleukin-6 (IL-6), transglutaminase-2 (TGM-2), and superoxide dismutase (SOD), which play critical roles in collagen and extracellular matrix metabolism in gingival enlargement.
methodsPrimary gingival fibroblasts were isolated from patients with amlodipine-induced gingival overgrowth (GO group) and from healthy gingival tissues (H group). Each group was divided into untreated and resveratrol-treated subgroups. Cell proliferation and viability at 24 and 48 h were assessed by MTT assay. The levels of TGF-β1, CTGF, COL-1, IL-6, TGM-2, and SOD were quantified using ELISA.
resultsMTT values were significantly higher in the GO group than in the H group at both 24 and 48 h (p = 0.01). Resveratrol treatment significantly decreased proliferation in the GO group at both time points (p < 0.001). In the GO group, resveratrol reduced TGF-β1 (p = 0.0090), CTGF (p = 0.0090), TGM-2 (p = 0.0088), COL-1 (p = 0.0139), and IL-6 (p = 0.050) levels at 24 h and significantly increased SOD levels (p = 0.0143).
conclusionResveratrol suppressed cellular proliferation without exerting cytotoxic effects in amlodipine-induced GO, while downregulating fibrosis markers (TGF-β1, CTGF, COL-1, IL-6, and TGM-2) and restoring diminished SOD synthesis. TRIAL REGISTIRATION: This study did not involve a clinical trial and therefore registration was not required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.